Adoption of new therapies in the treatment of Hepatitis: a verification of the accuracy of budget impact analysis to guide investment decisions-Reference-Cited by-同舟云学术

Adoption of new therapies in the treatment of Hepatitis: a verification of the accuracy of budget impact analysis to guide investment decisions

Published:2022-04-04 Issue:6 Volume:22 Page:927-939
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Faleiros Daniel Resende¹^ORCID,Nunes da Silva Everton²^ORCID,Santos Andreia C³^ORCID,Godman Brian B.⁴⁵⁶^ORCID,Goncalves Pereira Ramon⁷^ORCID,Guerra Junior Augusto A⁸^ORCID

Affiliation:

1. Nucleus Infectious and Parasitic Diseases, Tropical Medicine Centre, University of Brasilia, Brasília, Brazil

2. Faculty of Ceilândia, University of Brasilia, Brasília, Brazil

3. Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK

4. Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK

5. Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates

6. Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa

7. Faculty of Pharmacy, Federal University of Minas Gerais,Belo Horizonte, Minas Gerais, Brazil

8. Department of Social Pharmacy, Faculty of Pharmacy, Federal University of Minas Gerais. Belo Horizonte, Minas Gerais, Brazil

Funder

This study was financed in part by the Coordination for the Improvement of Higher Education Personnel (CAPES), Brazilian Ministry of Education

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2022.2057950

Reference97 articles.

1. How much will Herceptin really cost?

2. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?

3. Inequities in access to biologic and synthetic DMARDs across 46 European countries

4. Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications

5. Restrictions of Hepatitis C Treatment for Substance-Using Medicaid Patients: Cost Versus Ethics

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perceptions of and Preparedness for the Application of Pharmacoeconomics in Practice, among Final Year Bachelor of Pharmacy Students in South Africa: A National Cross-Sectional Study;Pharmacy;2023-03-14

2. Financial product investment decision model based on ultimate benefit;BCP Business & Management;2022-09-19